An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows
Asian Stocks Slide as AI Rally Pauses, South Korean Chipmakers Lead Regional Decline
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics
Is dark chocolate healthier than milk chocolate? 2 dietitians explain
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
France Faces Long Road to Economic Rebalancing as Weak Demand and High Rates Weigh, Says Citi
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 



